Levo-C (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, replenishing the depleted neurotransmitter in Parkinson's disease. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain and increasing the amount that reaches central nervous system sites.

The appropriate dose of Levo-C is individualized by the treating physician based on disease severity, patient response, and tolerability. Dosage regimens can vary widely, and any adjustments should be made under medical supervision.

Safety data for carbidopa/levodopa during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Levo-C, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levo-C (carbidopa/levodopa) is considered the most effective symptomatic therapy for motor control, whereas dopamine agonists or MAO‑B inhibitors are often used as adjuncts or early‑stage alternatives. Levo-C typically provides stronger symptom relief but may be associated with motor complications such as dyskinesia over long‑term use.

Levo-C tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Levo-C is taken orally, usually with a full glass of water. It may be taken with or without food, but high‑protein meals can interfere with absorption, so consistent timing relative to meals is recommended. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a clinician.

Serious adverse events include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, neuroleptic malignant syndrome, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience sudden confusion, severe dizziness, uncontrolled movements, or signs of an allergic reaction.

Levo-C is contraindicated in individuals with known hypersensitivity to carbidopa, levodopa, or any excipients, as well as patients with narrow‑angle glaucoma, malignant melanoma, or a history of severe cardiovascular disease. Caution is also advised for those with significant hepatic or renal impairment, and it should be avoided in patients taking non‑selective MAO inhibitors.